ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
Pink SheetEngland’s health technology assessment (HTA) agency, NICE, has formally agreed to reimburse Vertex / CRISPR Therapeutics AG ’s CRISPR/Cas9-based gene editing therapy Casgevy (exagamglogene autotemcel
ScripA total of 37 novel drugs were approved by the European Commission in 2024, a figure only marginally higher than the 36 products that were given the go-ahead in 2023. The 2024 and 2023 figures for new
In VivoA healthy total of 61 novel drugs were approved in the US in the course of 2024, but just a handful of these look certain to generate the multi-billion dollar sales that big pharma increasingly needs.